Janssen Pharmaceutica Nv

Dupont Pharmaceuticals Company

Bristol-myers Squibb Pharma Company

E.i. Dupont De Nemours and Company

Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Corporation

Mona Patel

Philip J Rybczynski

Maud J Urbanski

Xiaoyan Zhang

James David Rodgers

Mary Pat Beavers

Min Amy Xiang

Anthony J Cocuzza

Rodney Lawrence Parsons, Jr

Bruce E Maryanoff

Keith T Demarest

Haisheng Wang

Argyrios George Arvanitis

Michael J Costanzo

Joseph M Fortunak

Stephen C Yabut

Joseph Gunnet

Joseph Dudash

Yongzheng Zhang

Hiayan Bian

Richard Look

Soo Sung Ko

Rajagopal Bakthavatchalam

Steven P Seitz

Christine M Tarby

Barry L Johnson

Roxanne Zeck

Shelley R Rabel

Abdul Ezaz Mutlib

David Donald Christ

Min (Amy) Xiang

Jay Andrew Markwalder

Min A Xiang

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating glucokinase mediated disorders. More particularly, the compounds of the present invention are glucokinase modulators useful for treating disorders including, but not limited to, type II diabetes.

Dihydroisoindolones as allosteric modulators of glucokinase

The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

Substituted spiroheterocycles

The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.

Substituted indole-O-glucosides

Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.

Substituted indazole-O-glucosides

The invention is directed to nonpeptide substituted benzazepines of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension, among others disclosed. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

Substituted spirobenzazepines

[object Object]

The present invention relates to tricyclic 2-pyridone compounds of formula (I):or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors

Tricyclic compounds useful as HIV reverse transcriptase inhibitors

4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same

Growing community of inventors

Belle Mead, NJ, United States of America

Mona Patel